Information Provided By: 
Fly News Breaks for December 12, 2019
RHHBY, AZN, GMAB
Dec 12, 2019 | 05:32 EDT
Deutsche Bank analyst Richard Parkes downgraded Genmab (GMAB) to Hold from Buy with a DKK 1,570 price target. The analyst says the current valuation reflects the company's pipeline. AstraZeneca (AZN) and Roche (RHHBY) are his top large cap picks in European pharmaceuticals due to their "innovation advantage."
News For GMAB;AZN;RHHBY From the Last 2 Days
RHHBY
Apr 25, 2024 | 11:44 EDT
AZN
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.
AZN
Apr 25, 2024 | 05:49 EDT
RHHBY
Apr 24, 2024 | 06:33 EDT
RHHBY
Apr 24, 2024 | 06:30 EDT
